Facio expands Scientific Advisory Board
Leiden, the Netherlands – February 11, 2019
Facio announced today that Prof. Dr. Gerd Schnorrenberg has agreed to join Facio’s Scientific Advisory Board. His strong drug discovery and development expertise will support Facio in its ongoing efforts to generate, select and optimize drug development candidates for specific use in treating FSHD.
Gerd Schnorrenberg has extensive experience in pharmaceutical research and development in several therapeutic areas. He recently retired from Boehringer Ingelheim Pharma GmbH & Co KG, where he was Head of Research, Germany, and member of the International Research Committee overseeing all research activities. In the course of a career that spanned 36 years, he made many contributions to Boehringer Ingelheim’s research and development pipeline and drug approvals across a variety of disease domains. Gerd lectured in medicinal chemistry at Johannes Gutenberg University (Mainz, Germany) and received an honorary professorship from the German federal State of Rheinland-Pfalz. He received his PhD from the University of Bonn and spent a sabbatical at the University of California in San Diego and at Massachusetts Institute of Technology.
“I am delighted to support Facio’s exciting FSHD program and to contribute to identifying effective and innovative disease-modifying medicines to fight this debilitating disease. I am looking forward to working with Facio’s team of highly motivated and talented scientists,” said Gerd.
Facio’s R&D Director, Joris De Maeyer, commented: “Compounds fit for treating FSHD do not exist. They have to be designed and optimized. This requires very careful thought, experimentation and selection because a compound must meet many exacting criteria before it may become suitable as a future FSHD drug. Gerd’s deep and wide experience in drug discovery will help us maintain the high standards of rigor that we apply in our R&D. We are pleased by his willingness to contribute to the advancement of our therapies.”